[1]
|
Saeedi, P., Petersohn, I., Salpea, P., et al. (2019) Global and Regional Diabetes Prevalence Estimates for 2019 and Projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th Edition. Diabetes Research and Clin-ical Practice, 157, Article ID: 107843. https://doi.org/10.1016/j.diabres.2019.107843
|
[2]
|
Tan, S.Y., Wong, J., Yan, J.S., et al. (2019) Type 1 and 2 Diabetes Mellitus: A Review on Current Treatment Approach and Gene Therapy as Potential Inter-vention. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 13, 364-372. https://doi.org/10.1016/j.dsx.2018.10.008
|
[3]
|
Bommer, C., Heesemann, E., Sagalova, V., et al. (2017) The Global Eco-nomic Burden of Diabetes in Adults Aged 20-79 Years: A Cost-of-Illness Study. The Lancet Diabetes & Endocrinology, 5, 423-430.
https://doi.org/10.1016/S2213-8587(17)30097-9
|
[4]
|
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版) [J]. 国际内分泌代谢杂志, 2021, 41(5): 482-548.
|
[5]
|
Scheen, A.J. (2020) Sodium—Glucose Cotransporter Type 2 In-hibitors for the Treatment of Type 2 Diabetes Mellitus. Nature Reviews Endocrinology, 16, 556-577. https://doi.org/10.1038/s41574-020-0392-2
|
[6]
|
Wheeler, D.C., Stefánsson, B.V., Jongs, N., et al. (2021) Effects of Dapagliflozin on Major Adverse Kidney and Cardiovascular Events in Patients with Diabetic and Non-Diabetic Chronic Kidney Disease: A Prespecified Analysis from the DAPA-CKD Trial. The lancet Diabetes & Endocrinology, 9, 22-31.
https://doi.org/10.1016/S2213-8587(20)30369-7
|
[7]
|
Mosenzon, O., Raz, I., Wiviott, S.D., et al. (2022) Dapagliflozin and Prevention of Kidney Disease among Patients with Type 2 Diabetes: Post Hoc Analyses from the DECLARE-TIMI 58 Trial. Diabetes Care, 45, 2350-2359.
https://doi.org/10.2337/dc22-0382
|
[8]
|
Saisho, Y. (2020) SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes? Diseases, 8, Article 14.
https://doi.org/10.3390/diseases8020014
|
[9]
|
Nicholson, M.K., Ghazal Asswad, R. and Wilding, J.P. (2021) Dapagli-flozin for the Treatment of Type 2 Diabetes Mellitus—An Update. Expert Opinion on Pharmacotherapy, 22, 2303-2310.
https://doi.org/10.1080/14656566.2021.1953471
|
[10]
|
Kaku, K., Inoue, S., Matsuoka, O., et al. (2013) Efficacy and Safety of Dapagliflozin as a Monotherapy for Type 2 Diabetes Mellitus in Japanese Patients with Inadequate Glycaemic Control: A Phase II Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes, Obesity and Metabolism, 15, 432-440.
https://doi.org/10.1111/dom.12047
|
[11]
|
Yang, W.Y., Ma, J.H., Li, Y.M., et al. (2018) Dapagliflozin as Add-on Therapy in Asian Patients with Type 2 Diabetes Inadequately Controlled on Insulin with or without Oral Antihyperglycemic Drugs: A Randomized Controlled Trial. Journal of Diabetes, 10, 589-599. https://doi.org/10.1111/1753-0407.12634
|
[12]
|
严玲玲, 林树云, 马丽丽. 达格列净联合二甲双胍治疗2型糖尿病的临床疗效和安全性[J]. 临床合理用药杂志, 2022, 15(16): 91-93.
|
[13]
|
马静. 达格列净治疗2型糖尿病患者的应用进展[J]. 现代诊断与治疗, 2021, 32(16): 2544-2545, 2589.
|
[14]
|
Cai, X., Yang, W., Gao, X., et al. (2018) The Association between the Dosage of SGLT2 Inhibitor and Weight Re-duction in Type 2 Diabetes Patients: A Meta-Analysis. Obesity, 26, 70-80. https://doi.org/10.1002/oby.22066
|
[15]
|
Chen, M.B., Wang, H., Cui, W.Y., Xu, H.L., et al. (2021) Effect of SGLT Inhibitors on Weight and Lipid Metabolism at 24 Weeks of Treatment in Patients with Diabetes Mellitus: A Systematic Review and Network Meta-Analysis. Medicine, 100, e24593. https://doi.org/10.1097/MD.0000000000024593
|
[16]
|
Sternlicht, H. and Bakris, G.L. (2019) Blood Pressure Lowering and Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis. Current Hypertension Reports, 21, Article No. 12.
https://doi.org/10.1007/s11906-019-0920-4
|
[17]
|
Jia, G. and Sowers, J.R. (2021) Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease. Hypertension, 78, 1197-1205. https://doi.org/10.1161/HYPERTENSIONAHA.121.17981
|
[18]
|
Morisco, C., Condorelli, G., Trimarco, V., et al. (2005) Akt Mediates the Cross-Talk Between β-Adrenergic and Insulin Receptors in Neonatal Cardiomyocytes. Circulation Research, 96, 180-188.
https://doi.org/10.1161/01.RES.0000152968.71868.c3
|
[19]
|
Hao, Z., Sun, Y., Wen, Y., et al. (2020) Effects and Mecha-nisms of Dapagliflozin Treatment on Ambulatory Blood Pressure in Diabetic Patients with Hypertension. Medical Science Mon-itor, 26, e925987.
https://doi.org/10.12659/MSM.925987
|
[20]
|
Gallo, L.A., Ward, M.S., Fotheringham, A.K., et al. (2016) Once Daily Ad-ministration of the SGLT2 Inhibitor, Empagliflozin, Attenuates Markers of Renal Fibrosis without Improving Albuminuria in Diabetic db/db Mice. Scientific Reports, 6, Article No. 26428. https://doi.org/10.1038/srep26428
|
[21]
|
Kravtsova, O., Bohovyk, R., Levchenko, V., et al. (2022) SGLT2 Inhibition Effect on Salt-Induced Hypertension, RAAS, and Na+ Transport in Dahl SS Rats. American Journal of Physiology-Renal Physiology, 322, F692-F707.
https://doi.org/10.1152/ajprenal.00053.2022
|
[22]
|
张楠, 阮丹杰, 刘新颖, 等. 达格列净对2型糖尿病合并高血压患者醛固酮/肾素浓度比值的影响[J]. 中华糖尿病杂志, 2022, 14(1): 63-67.
|
[23]
|
Akash, M.S.H., Rehman, K. and Liaqat, A. (2018) Tumor Necrosis Factor-α: Role in Development of Insulin Resistance and Pathogenesis of Type 2 Diabetes Mellitus. Journal of Cellular Biochemistry, 119, 105-110.
https://doi.org/10.1002/jcb.26174
|
[24]
|
Akbari, M. and Hassan-Zadeh, V. (2018) IL-6 Signalling Pathways and the De-velopment of Type 2 Diabetes. Inflammopharmacology, 26, 685-698. https://doi.org/10.1007/s10787-018-0458-0
|
[25]
|
Nedosugova, L.V., Markina, Y.V., Bochkareva, L.A., et al. (2022) In-flammatory Mechanisms of Diabetes and Its Vascular Complications. Biomedicines, 10, Article 1168. https://doi.org/10.3390/biomedicines10051168
|
[26]
|
Wang, C., Qin, Y., Zhang, X., et al. (2022) Effect of Dapagliflozin on Indicators of Myocardial Fibrosis and Levels of Inflammatory Factors in Heart Failure Patients. Disease Markers, 2022, Article ID: 5834218.
https://doi.org/10.1155/2022/5834218
|
[27]
|
Contreras-Bolívar, V., García-Fontana, B., García-Fontana, C. and Muñoz-Torres, M. (2021) Mechanisms Involved in the Relationship between Vitamin D and Insulin Resistance: Impact on Clinical Practice. Nutrients, 13, Article 3491.
https://doi.org/10.3390/nu13103491
|
[28]
|
骆莹莹, 黄若妃, 李可. 达格列净对2型糖尿病患者25(OH)D_3及炎症因子表达的影响[J]. 重庆医学, 2022, 51(12): 2024-2027.
|
[29]
|
赵梦萍, 孔祥栋, 陈肖蓉, 等. 达格列净治疗早期糖尿病肾病的疗效及对血清TNF-α、IL-6水平的影响[J]. 中国现代医生, 2022, 60(14): 33-36.
|
[30]
|
Leoncini, G., Russo, E., Bus-salino, E., Barnini, C., et al. (2021) SGLT2is and Renal Protection: From Biological Mechanisms to Real-World Clinical Bene-fits. International Journal of Molecular Sciences, 22, Article 4441.
https://doi.org/10.3390/ijms22094441
|
[31]
|
Ambarsari, C.G., Pardede, S.O., Fazlur Rahman, F.H., et al. (2021) Role of Dipstick Albuminuria in Progression of Paediatric Chronic Kidney Disease. Journal of the Pakistan Medical Association, 71, S103-S106.
|
[32]
|
Wu, L., Liu, C., Chang, D.Y., et al. (2021) Annexin A1 Alleviates Kidney Injury by Promoting the Resolu-tion of Inflammation in Diabetic Nephropathy. Kidney International, 100, 107-121. https://doi.org/10.1016/j.kint.2021.02.025
|
[33]
|
Kelly, M.S., Lewis, J., Huntsberry, A.M., Dea, L. and Portillo, I. (2019) Efficacy and Renal Outcomes of SGLT2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease. Postgraduate Medicine, 131, 31-42.
https://doi.org/10.1080/00325481.2019.1549459
|
[34]
|
Bailey, C.J., Day, C. and Bellary, S. (2022) Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease. Current Diabetes Reports, 22, 39-52. https://doi.org/10.1007/s11892-021-01442-z
|
[35]
|
Kanbay, M., Tapoi, L., Ureche, C., et al. (2022) Effect of Sodi-um-Glucose Cotransporter 2 Inhibitors on Hemoglobin and Hematocrit Levels in Type 2 Diabetes: A Systematic Review and Meta-Analysis. International Urology and Nephrology, 54, 827-841. https://doi.org/10.1007/s11255-021-02943-2
|
[36]
|
Heerspink, H.J., Stefánsson, B.V., Correa-Rotter, R., et al. (2020) Dapagliflozin in Patients with Chronic Kidney Disease. The New England Journal of Medicine, 383, 1436-1446. https://doi.org/10.1056/NEJMoa2024816
|
[37]
|
Heerspink, H.J.L., Jongs, N., Chertow, G.M., et al. (2021) Effect of Dapagliflozin on the Rate of Decline in Kidney Function in Patients with Chronic Kidney Disease with and without Type 2 Dia-betes: A Prespecified Analysis from the DAPA-CKD Trial. The Lancet Diabetes & Endocrinology, 9, 743-754.
https://doi.org/10.1016/S2213-8587(21)00242-4
|
[38]
|
American Diabetes Association Professional Practice Committee (2022) 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022. Diabetes Care, 45, S125-S143.
https://doi.org/10.2337/dc22-S009
|
[39]
|
Wiviott, S.D., Raz, I., Bonaca, M.P., et al. (2019) Dapagliflozin and Cardiovascu-lar Outcomes in Type 2 Diabetes. The New England Journal of Medicine, 380, 347-357. https://doi.org/10.1056/NEJMoa1812389
|
[40]
|
Zelniker, T.A., Bonaca, M.P., Furtado, R.H., et al. (2020) Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial. Cir-culation, 141, 1227-1234.
https://doi.org/10.1161/CIRCULATIONAHA.119.044183
|
[41]
|
Ong, H.T., Teo, Y.H., Teo, Y.N., et al. (2022) Effects of Sodium/Glucose Cotransporter Inhibitors on Atrial Fibrillation and Stroke: A Meta-Analysis. Journal of Stroke and Cerebro-vascular Diseases, 31, Article ID: 106159.
https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.106159
|
[42]
|
McMurray, J.J.V., Solomon, S.D., Inzucchi, S.E., et al. (2019) Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. The New England Journal of Medicine, 381, 1995-2008.
https://doi.org/10.1056/NEJMoa1911303
|
[43]
|
Vaduganathan, M., Docherty, K.F., Claggett, B.L., et al. (2022) SGLT-2 Inhibitors in Patients with Heart Failure: A Comprehensive Meta-Analysis of Five Randomised Controlled Trials. The Lancet, 400, 757-767.
https://doi.org/10.1016/S0140-6736(22)01429-5
|
[44]
|
Solomon, S.D., McMurray, J.J.V., Claggett, B., et al. (2022) Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. The New England Journal of Medicine, 387, 1089-1098.
https://doi.org/10.1056/NEJMoa2206286
|
[45]
|
Jhund, P.S., Kondo, T., Butt, J.H., et al. (2022) Dapagliflozin across the Range of Ejection Fraction in Patients with Heart Failure: A Patient-Level, Pooled Meta-Analysis of DAPA-HF and DELIVER. Nature Medicine, 28, 1956-1964.
https://doi.org/10.1038/s41591-022-01971-4
|
[46]
|
Lopaschuk, G.D. and Verma, S. (2020) Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC: Basic to Translational Science, 5, 632-644.
https://doi.org/10.1016/j.jacbts.2020.02.004
|
[47]
|
Grandoch, M., Kohlmorgen, C., Melchior-Becker, A., et al. (2016) Loss of Biglycan Enhances Thrombin Generation in Apolipoprotein E-Deficient Mice: Implications for Inflammation and Atheroscle-rosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 36, e41-e50. https://doi.org/10.1161/ATVBAHA.115.306973
|
[48]
|
Kohlmorgen, C., Gerfer, S., Feldmann, K., et al. (2021) Dapagli-flozin Reduces Thrombin Generation and Platelet Activation: Implications for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus. Diabetologia, 64, 1834-1849.
https://doi.org/10.1007/s00125-021-05498-0
|
[49]
|
Lee, T.M., Chang, N.C. and Lin, S.Z. (2017) Dapagliflozin, a Selective SGLT2 Inhibitor, Attenuated Cardiac Fibrosis by Regulating the Macrophage Polarization via STAT3 Signaling in Infarcted Rat Hearts. Free Radical Biology and Medicine, 104, 298-310. https://doi.org/10.1016/j.freeradbiomed.2017.01.035
|
[50]
|
Baartscheer, A., Schumacher, C.A., Wüst, R.C., et al. (2017) Empagliflozin Decreases Myocardial Cytoplasmic Na+ through Inhibition of the Cardiac Na+/H+ Exchanger in Rats and Rabbits. Diabetologia, 60, 568-573.
https://doi.org/10.1007/s00125-016-4134-x
|
[51]
|
Chung, Y.J., Park, K.C., Tokar, S., et al. (2021) Off-Target Effects of Sodium-Glucose Co-Transporter 2 Blockers: Empagliflozin Does Not Inhibit Na+/H+ Exchanger-1 or Lower [Na+]i in the Heart. Cardiovascular Research, 117, 2794-2806. https://doi.org/10.1093/cvr/cvaa323
|
[52]
|
Xu, B., Li, S.Q., Kang, B. and Zhou, J.C. (2022) The Current Role of Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes Mellitus Management. Cardiovascular Diabetology, 21, Article No. 83.
https://doi.org/10.1186/s12933-022-01512-w
|
[53]
|
Davidson, J.A., Sukor, N., Hew, F.L., Mohamed, M. and Hussein, Z. (2023) Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Asian Type 2 Diabetes Populations. Journal of Diabetes Investigation, 14, 167-182.
https://doi.org/10.1111/jdi.13915
|
[54]
|
Chowdhury, T., Gousy, N., Bellamkonda, A., et al. (2022) Fournier’s Gangrene: A Coexistence or Consanguinity of SGLT-2 Inhibitor Therapy. Cureus, 14, e27773. https://doi.org/10.7759/cureus.27773
|
[55]
|
Qiu, M., Ding, L.L., Zhang, M. and Zhou, H.R. (2021) Safety of Four SGLT2 Inhibitors in Three Chronic Diseases: A Meta-Analysis of Large Randomized Trials of SGLT2 Inhibitors. Diabetes and Vascu-lar Disease Research, 18, No. 2.
https://doi.org/10.1177/14791641211011016
|
[56]
|
Hapca, S., Siddiqui, M.K., Kwan, R.S.Y., et al. (2021) The Relation-ship between AKI and CKD in Patients with Type 2 Diabetes: An Observational Cohort Study. Journal of the American Society of Nephrology, 32, 138-150.
https://doi.org/10.1681/ASN.2020030323
|
[57]
|
Zhuo, M., Paik, J.M., Wexler, D.J., et al. (2022) SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults with Type 2 Diabetes. American Journal of Kidney Diseases, 79, 858-867.E1.
https://doi.org/10.1053/j.ajkd.2021.09.015
|